CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis

Posted: July 19, 2022 at 2:15 am

SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- Cells for Cells ("C4C"), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France.

See the article here:
CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis

Related Posts